Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1

Our results indicate that selumetinib is an effective and safe treatment for pediatric patients with symptomatic, inoperable plexiform neurofibromas. Further larger-scale randomized controlled studies are needed to confirm the long-term outcome of patients treated with this drug.